Skip to content
HowShorted

Perspective Therapeutics, Inc. short interest in 2020

In 2020, Perspective Therapeutics, Inc.'s disclosed short interest ran from 2.50% of shares outstanding on 15 Jan 2020 to 1.19% on 31 Dec 2020, a change of -1.31 percentage points. The year's high was 4.37% on 14 Feb 2020 and its low 0.92% on 15 Dec 2020, averaging 2.49% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 8.71 days on 15 Oct 2020. Full history: Perspective Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Perspective Therapeutics, Inc. in 2020

2020 in figures

Start of year
2.50% (15 Jan 2020)
End of year
1.19% (31 Dec 2020)
Change
-1.31 pp
High
4.37% (14 Feb 2020)
Low
0.92% (15 Dec 2020)
Average
2.49%
Highest days to cover
8.71 (15 Oct 2020)
SEC filings marked
8

Every report in 2020

Perspective Therapeutics, Inc. short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 20202.50%2.59
31 Jan 20203.92%2.92
14 Feb 20204.37%4.88results (8-K), 10-Q filed
28 Feb 20203.98%5.07
13 Mar 20203.65%5.51
31 Mar 20203.15%7.22
15 Apr 20202.93%6.61
30 Apr 20202.93%7.65
15 May 20203.68%2.73results (8-K), 10-Q filed
29 May 20203.21%5.33
15 Jun 20202.56%3.44
30 Jun 20202.32%4.53
15 Jul 20202.26%3.49
31 Jul 20202.25%5.93
14 Aug 20202.28%3.66
31 Aug 20202.14%5.02
15 Sep 20202.21%6.71
30 Sep 20201.91%2.38results (8-K), 10-K filed
15 Oct 20201.87%8.71
30 Oct 20201.40%1.00
13 Nov 20201.21%1.43results (8-K), 10-Q filed
30 Nov 20201.04%1.00
15 Dec 20200.92%1.00
31 Dec 20201.19%1.00

See also: Perspective Therapeutics, Inc.'s full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.